×
About 40,078 results

ALLMedicine™ Gastric Cancer Center

Research & Reviews  14,785 results

Effect of gastric cancer screening on long-term survival of gastric cancer patients: re...
https://doi.org/10.1007/s00535-022-01878-4 10.3322/caac.21660 10.1002/ijc.11183 10.1038/bjc.2014.608 10.1053/j.gastro.2017.01.029 10.1245/ASO.2006.04.028 10.1002/ijc.2910600106 10.1016/S1470-2045(08)70072-X 10.1016/j.gie.2016.02.028 10.1093/jjco/hyy077 10.1136/gutjnl-2015-310356 10.4143/crt.2021.291 10.1186/1471-230X-13-104 10.4143/crt.2020.610 10.1111/hel.12463 10.4143/crt.2016.186 10.1111/apm.1965.64.1.31 10.1158/1055-9965.EPI-09-0250 10.1016/j.jval.2014.03.733 10.1002/cncr.10646 10.1371/journal.pone.0126796 10.1371/journal.pone.0079088 10.1111/cas.12829 10.1245/s10434-019-07455-z 10.1097/00042737-200512000-00013 10.1371/journal.pone.0050041 10.5946/ce.2014.47.6.490 10.1007/PL00011735 10.1097/MEG.0b013e328318ed42 10.1002/cncr.27495 10.1207/S15327914NC381_5 10.3748/wjg.15.3653 10.1186/s12885-015-1328-4 10.4143/crt.2021.482 10.1002/cncr.32753 10.3748/wjg.v16.i2.245 10.1093/annonc/mdj007 10.1016/S0959-8049(97)10098-3 10.1371/journal.pone.0089655 10.4143/crt.2016.243 10.1615/JEnvironPatholToxicolOncol.2017024821 10.5009/gnl16397 10.4143/crt.2015.264 10.1111/j.1523-5378.2011.00859.x 10.1007/978-3-319-40618-3
Journal of Gastroenterology; Luu XQ, Lee K et. al.

May 15th, 2022 - Gastric cancer (GC) is the most common cancer type in Korea. Korean National Cancer Screening Program (KNCSP) offer either upper gastrointestinal series (UGIS) or upper endoscopy biennially for adults aged ≥ 40. This study aimed to investigate the...

Native and Indigenous Populations and Gastric Cancer: A Worldwide Review.
https://doi.org/10.3390/ijerph19095437
International Journal of Environmental Research and Publi... Cordova-Marks FM, Carson WO et. al.

May 15th, 2022 - Gastric cancer is a worldwide concern, particularly for Indigenous populations who face greater disparities in healthcare. With decreased access to screening and critical treatment delays, this group is experiencing adverse health effects. To dete...

see more →

Guidelines  23 results

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0008
Journal of the National Comprehensive Cancer Network : JN... Ajani JA, D'Amico TA et. al.

Feb 8th, 2022 - Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor p...

ACR Appropriateness Criteria® Epigastric Pain.
https://doi.org/10.1016/j.jacr.2021.08.006
Journal of the American College of Radiology : JACR; , Vij A et. al.

Nov 20th, 2021 - Epigastric pain can have multiple etiologies including myocardial infarction, pancreatitis, acute aortic syndromes, gastroesophageal reflux disease, esophagitis, peptic ulcer disease, gastritis, duodenal ulcer disease, gastric cancer, and hiatal h...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Hereditary diffuse gastric cancer: updated clinical practice guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116190
The Lancet. Oncology; Blair VR, McLeod M et. al.

Aug 8th, 2020 - Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour...

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
https://doi.org/10.1097/AOG.0000000000003562
Obstetrics and Gynecology;

Nov 26th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  565 results

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
https://clinicaltrials.gov/ct2/show/NCT03092518

May 13th, 2022 - Background: An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the U.S. The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence. Laparoscopy with peritonea...

Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy
https://clinicaltrials.gov/ct2/show/NCT05371249

May 12th, 2022 - Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized. Extended proton pump inhibitor (PPI)-base...

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
https://clinicaltrials.gov/ct2/show/NCT05071053

May 12th, 2022 - 34 weeks (up to 4 weeks for screening, a median of 18 weeks for treatment, and a median of 12 weeks for end-of-treatment assessments and the safety follow-up visit).

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
https://clinicaltrials.gov/ct2/show/NCT02065765

May 11th, 2022 - The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophag...
https://clinicaltrials.gov/ct2/show/NCT04661150

May 9th, 2022 - This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gast...

see more →

News  648 results

Finding Your Wolfpack in Academic Medicine
https://www.medscape.com/viewarticle/973400

May 10th, 2022 - I remember it like it was yesterday: It was my first American Society of Clinical Oncology (ASCO) Annual Meeting. I was a PGY-1 and I was presenting about gastric cancer in Hispanic individuals and the disparities that this population experiences ...

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors
https://www.onclive.com/view/sot101-plus-pembrolizumab-elicits-encouraging-efficacy-in-advanced-solid-tumors

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

FDA Issues Complete Response Letter to Toripalimab for Nasopharyngeal Carcinoma
https://www.onclive.com/view/fda-issues-complete-response-letter-to-toripalimab-for-nasopharyngeal-carcinoma

May 2nd, 2022 - The FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking the approval of toripalimab for use in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent...

Gastric cancer: Add-on apatinib to neoadjuvant chemotherapy shows good response
https://www.mdedge.com/hematology-oncology/article/254103/gastrointestinal-cancer/gastric-cancer-add-apatinib-neoadjuvant

Apr 26th, 2022 - Key clinical point: Neoadjuvant treatment with apatinib in combination with oxaliplatin and capecitabine shows good response and a manageable safety profile in patients with locally advanced adenocarcinoma of the stomach or gastroesophageal juncti.

APOA2 May Serve as a New Biomarker for Gastric Cancer
https://www.medscape.com/viewarticle/972679

Apr 25th, 2022 - The study featured in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways APOA2 is overexpressed in gastric adenocarcinoma compared with normal gastric tissue samples. It appears to be i...

see more →

Patient Education  7 results see all →